



ADULT MEDICATION GUIDELINE

Octreotide

Scope (Staff):	All WNHS Staff
Scope (Area):	Obstetrics and Gynaecology

This document should be read in conjunction with the [Disclaimer](#).

Quick Links

[Dose](#)

[Administration](#)

[Monitoring](#)

[Pregnancy and Breastfeeding](#)

Restrictions

[Formulary: Restricted](#)

Medication Class

Somatostatin Analogues

Presentation

Ampoule: 100microg/mL

Storage

Store at 2°C to 8°C (Refrigerate. Do not freeze). Protect from light.

Sandostatin and Octreotide MaxRx ampoules are stable for 2 weeks below 25 °C protected from light. Do not return to the fridge.

Dose

Rarely used and no longer recommended by Therapeutic Guidelines®; seek advice from palliative care consultant.

Bowel obstruction

Subcut injection:

50 - 100microg 2 to 3 times a day

Subcut infusion:

300 microg/24 hours

Can be titrated up to 900microg per 24hours if required but usually in the range of 300 – 600microg per 24 hours

Administration**SUBCUT injection**

Allow to reach room temperature before use. Injection is painful especially if the solution is not at room temperature.

Rotate the site of the injection.

*May be given as a continuous subcutaneous infusion in palliative care. Dilute to a large volume to avoid inflammatory skin reactions.

Monitoring

May cause hyper or hypoglycaemia, blood glucose monitoring may be required.

Thyroid function if used long-term

Pregnancy

1st Trimester: Monitoring required

2nd Trimester: Monitoring required

3rd Trimester: Monitoring required

For more information, please contact [KEMH Obstetric Medicines Information Service](#).

Breastfeeding

Monitoring required

For more information, please contact [KEMH Obstetric Medicines Information Service](#).

Comments

- To reduce local discomfort, it is recommended that the solution reaches room temperature before injection.

Related Policies, Procedures & Guidelines

WNHS Clinical Practice Guidelines:

[Palliative Care](#)

[Niki t34 syringe pump: Continuous subcutaneous infusion management](#)

Other Hospital Guidelines:

[FSH Pharmacy Department: Intravenous Drug Administration Guideline: Octreotide](#)

[SCGH Medication Management Guidelines: High Output Stoma](#)

References









Society of Hospital Pharmacists of Australia. Octreotide. In: Australian Injectable Drugs Handbook [Internet]. [St Leonards, New South Wales]: Health Communication Network; 2021 Nov [cited 2021 Dec 23]. Available from: <http://aidh.hcn.com.au>

The Royal Women's Hospital. Octreotide. In: Pregnancy and Breastfeeding Medicines Guide [Internet]. Parkville (Victoria): The Royal Women's Hospital; 2021 [cited 2021 Dec 23]. Available from: <https://thewomenspbmg.org.au/>

Australian Medicines Handbook. Octreotide. In: Australian Medicines Handbook [Internet]. Adelaide (South Australia): Australian Medicines Handbook; 2021 July [cited 2021 Dec 23]. Available from: <https://amhonline.amh.net.au/>

Therapeutic Guidelines. Bowel obstruction in palliative care. In: eTG complete [Internet]. West Melbourne (Victoria): Therapeutic Guidelines; 2018 [cited 2021 Dec 23]. Available from: <https://tgldcdp.tg.org.au>

MIMS Australia. Octreotide GH. In: MIMS Online [Internet]. St Leonards (New South Wales): MIMS Australia; 2021 Jan [cited 2021 Dec 23]. Available from: <https://www.mimsonline.com.au>

Keywords	Octreotide, Bowel Obstruction, Palliative Care				
Document Owner:	Chief Pharmacist				
Author/ Reviewer	KEMH Pharmacy Department				
Version Info:	5.0				
Date First Issued:	Apr 2015	Last Reviewed:	Apr 2022	Review Date:	Apr 2025
Endorsed by:	Medicines and Therapeutics Committee			Date:	04/05/2022
NSQHS Standards Applicable:	<input checked="" type="checkbox"/>  Std 1: Clinical Governance <input type="checkbox"/>  Std 2: Partnering with Consumers <input type="checkbox"/>  Std 3: Preventing and Controlling Healthcare Associated Infection <input checked="" type="checkbox"/>  Std 4: Medication Safety		<input type="checkbox"/>  Std 5: Comprehensive Care <input type="checkbox"/>  Std 6: Communicating for Safety <input type="checkbox"/>  Std 7: Blood Management <input type="checkbox"/>  Std 8: Recognising and Responding to Acute Deterioration		
Printed or personally saved electronic copies of this document are considered uncontrolled. Access the current version from WNHS HealthPoint.					

The health impact upon Aboriginal people has been considered, and where relevant incorporated and appropriately addressed in the development of this document (insert ISD Number). (Please refer to the Aboriginal Health Impact Statement and Declaration for Department of Health and Health Service Provider Guidelines – please delete once you have completed this).

This document can be made available in alternative formats on request for a person with a disability.

© Women and Newborn Health Service 2022

Copyright of this material is vested in the State of Western Australia unless otherwise indicated. Apart from any fair dealing for the purposes of private study, research, criticism or review, as permitted under the provisions of the Copyright Act 1968, no part may be reproduced or re-used for any purposes whatsoever without written permission of the State of Western Australia.